Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as a solution for injection for intravenous use. It is employed in the treatment of hairy cell leukemia and multiple sclerosis, targeting malignant lymphocytes and modulating immune activity in the respective patient populations.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution aligned to EU regulatory standards.

Leustatin (cladribine) is used in hematologic malignancies and autoimmune neurologic disease.

Hairy cell leukemia: induces remission by selectively depleting malignant B‑lymphocytes. Multiple sclerosis: reduces relapse frequency by targeting pathogenic lymphocytes in the central nervous system.

Cladribine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Fatigue - Fever - Headache - Lymphopenia - Injection site reactions

Serious or Rare Side Effects: - Severe opportunistic infections - Autoimmune hemolytic anemia - Progressive multifocal leukoencephalopathy - Secondary malignancies - Profound lymphopenia requiring hospitalization

When using Leustatin, several precautionary measures should be observed to ensure patient safety.

Blood count monitoring: perform complete blood counts regularly to detect lymphopenia or neutropenia. Infection risk assessment: screen for active infections before initiating therapy. Live vaccine avoidance: do not administer live attenuated vaccines during treatment. Renal/hepatic function: evaluate organ function as dose adjustments may be needed. Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent cytotoxic chemotherapy: may increase myelosuppression. - Live attenuated vaccines: heightened risk of infection. - Potent immunosuppressants (e.g., azathioprine): additive immunosuppression.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., acyclovir): monitor for additive toxicity. - Vaccines (non‑live): assess immune response. - CYP450 modulators: observe for altered drug levels if co‑administered.